Antidepressant-Associated Treatment Emergent Mania: A Meta-Analysis to Guide Risk Modeling Pharmacogenomic Targets of Potential Clinical Value

Nicolas A. Nuñez, Brandon J. Coombes, Lindsay Melhuish Beaupre, Francisco Romo-Nava, Manuel Gardea-Resendez, Aysegul Ozerdem, Marin Veldic, Balwinder Singh, Jorge A. Sanchez Ruiz, Alfredo Cuellar-Barboza, Jonathan G. Leung, Miguel L. Prieto, Susan L. McElroy, Joanna M. Biernacka, Mark A. Frye*

*Autor correspondiente de este trabajo

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

Resumen

Background The purpose of this study was to review the association between the SLC6A4 5-HTTLPR polymorphism and antidepressant (AD)-associated treatment emergent mania (TEM) in bipolar disorder alongside starting a discussion on the merits of developing risk stratification models to guide when not to provide AD treatment for bipolar depression. Methods Studies that examined the association between clinical and genetic risk factors, specifically monoaminergic transporter genetic variation, and TEM were identified. A meta-analysis was performed using the odds ratio to estimate the effect size under the Der-Simonian and Laird model. Results Seven studies, referencing the SLC6A4 5-HTTLPR polymorphism and TEM (total N = 1578; TEM+ =594, TEM- = 984), of 142 identified articles were included. The time duration between the start of the AD to emergence of TEM ranged from 4 to 12 weeks. There was a nominally significant association between the s allele of the 5-HTTLPR polymorphism and TEM (odds ratio, 1.434; 95% confidence interval, 1.001-2.055; P = 0.0493; I2 = 52%). No studies have investigated norepinephrine or dopamine transporters. Conclusion Although the serotonin transporter genetic variation is commercially available in pharmacogenomic decision support tools, greater efforts, more broadly, should focus on complete genome-wide approaches to determine genetic variants that may contribute to TEM. Moreover, these data are exemplary to the merits of developing risk stratification models, which include both clinical and biological risk factors, to guide when not to use ADs in bipolar disorder. Future studies will need to validate new risk models that best inform the development of personalized medicine best practices treating bipolar depression.

Idioma originalInglés
Páginas (desde-hasta)428-433
Número de páginas6
PublicaciónJournal of Clinical Psychopharmacology
Volumen43
N.º5
DOI
EstadoPublicada - 1 sep. 2023

Nota bibliográfica

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.

Huella

Profundice en los temas de investigación de 'Antidepressant-Associated Treatment Emergent Mania: A Meta-Analysis to Guide Risk Modeling Pharmacogenomic Targets of Potential Clinical Value'. En conjunto forman una huella única.

Citar esto